Why the study?
Does furosemide alter the lipoprotein profile and postherapin plasma lipase activities in patients with chronic renal failure?
Does furosemide alter the lipoprotein profile and postherapin plasma lipase activities in patients with chronic renal failure?
Furosemide administration in patients with chronic renal failure reversibly increases VLDL cholesterol and VLDL triglyceride levels.
Furosemide may reversibly elevate VLDL lipids in chronic renal failure; leaves open effects on cardiovascular risk.
The effect of furosemide on the lipoprotein profile and the activities of postherapin plasma lipases were studied in 12 patients with chronic renal failure. The concentrations of serum total, VLDL and LDL triglycerides were significantly higher and the concentration of HDL triglyceride was significantly lower in the patients with renal failure than in healthy controls. HDL cholesterol was significantly lower in the patients than in the controls. The activity of postherapin lipoprotein lipase was significantly lower in the patients than in the controls. The introduction of furosemide induced a significant increase in the concentrations of VLDL cholesterol and VLDL triglyceride. These changes were reversed when the drug treatment was discontinued. Postherapin lipase activities were not further altered by furosemide.
No takes yet. Share an insight, caveat, or question.
Pasternack et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: